Continuing Challenges in Advancing Preclinical Science in Skeletal Cell-Based Therapies and Tissue Regeneration
Authors:
- 22 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 33 (10) , 1721-1728
Abstract
: Cell-based therapies hold much promise for musculoskeletal medicine; however, this rapidly growing field faces a number of challenges. Few of these therapies have proven clinical benefit, and an insufficient regulatory environment has allowed for widespread clinical implementation without sufficient evidence of efficacy. The technical and biological complexity of cell-based therapies has contributed to difficulties with reproducibility and mechanistic clarity. In order to aid in addressing these challenges, we aim to clarify the key issues in the preclinical cell therapy field, and to provide a conceptual framework for advancing the state of the science. Broadly, these suggestions relate to: (i) delineating cell-therapy types and moving away from “catch-all” terms such as “stem cell” therapies; (ii) clarifying descriptions of cells and their processing; and (iii) increasing the standard of in vivo evaluation of cell-based therapy experiments to determining cell fates. Further, we provide an overview of methods for experimental evaluation, data sharing, and professional society participation that would be instrumental in advancing this field. © 2018 American Society for Bone and Mineral Research.Keywords
Funding Information
- National Institutes of Health
- National Institute of Dental and Craniofacial Research ((ZIA DE000380))
- Nebraska Department of Health and Human Services
This publication has 50 references indexed in Scilit:
- Osterix-Cre Labeled Progenitor Cells Contribute to the Formation and Maintenance of the Bone Marrow StromaPLOS ONE, 2013
- Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cellsBMC Medicine, 2013
- In Vivo Fate Mapping Identifies Mesenchymal Progenitor CellsStem Cells, 2012
- Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacityJournal of Bone and Mineral Research, 2010
- Parabiosis model does not show presence of circulating osteoprogenitor cellsGenesis, 2010
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008
- Small animal bone biomechanicsBone, 2008
- Commercial Antibodies: The Good, Bad, and Really UglyJournal of Histochemistry & Cytochemistry, 2008
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Allogeneic marrow stromal cells are immune rejected by MHC class I– and class II–mismatched recipient miceBlood, 2005